Press releases

EG 427 Announces Attendance at Conferences in H1 2024

read more >

EG 427 Announces New Preclinical Results from Multiple Studies of EG110A in NDO and OAB

read more >

EG 427 Appoints Don Haut, Ph.D as Chief Business Officer and Opens US Headquarters

read more >

EG 427 Announces Positive Preclinical Results from EG110A IND-Enabling Study in Neurogenic Detrusor Overactivity and Overactive Bladder

read more >

EG 427 to hold poster presentation on lead asset EG110A at ESGCT

read more >

EG 427 announces attendance to multiple upcoming conferences in fall 2023

read more >

EG 427 presents positive preclinical data on lead asset EG110A at International Continence Society meeting

read more >

EG 427 announces final Series A closing, achieving €18 million in total funds raised

read more >

EG 427 announces that Dr. Greg Sarek, VP Research will be presenting at the 3rd annual Next Generation Gene Therapy Vectors conference

read more >

EG 427 appoints Ralph Laufer as new member to Board of Directors

read more >

EG 427 announces attendance to multiple upcoming conferences

EG 427 announces attendance to multiple upcoming conferences in Europe and US.

read more >

EG 427 announces issuance of the first 2 patents for its HSV-based gene therapy treatment.

EG 427 announces issuance of the first 2 patents in Europe and Japan protecting its first product EG110A.

read more >

EG 427 Appoints New Members To Board of Directors and Scientific Advisory Board

EG 427 Appoints New Members To Board of Directors and Scientific Advisory Board

read more >

EG 427 appoints Chief Medical Officer

EG 427 announces the appointment of Cornelia Haag-Molkenteller as Chief Medical Officer

read more >

EG 427 completes Series A financing

EG 427 announces €12 million Series A financing to advance its HSV-1 based gene therapy

read more >

Appointment of new VP of Research

EG 427 appoints Grzegorz Sarek, Ph.D., as Vice President of Research

read more >

News

Pharmaceutiques - Article on EG110A
Pharmaceutiques - Article on EG110A

read more >

Bladder Buzz talks about our innovative approach to NDO
Bladder Buzz talks about our innovative approach to NDO

read more >

EG 427 - a success story
EG 427 - a success story

EG 427 is the success story of the month presented by The SATT Network.

read more >

EG 427 wins key funding from Bpifrance
EG 427 wins key funding from Bpifrance

EG 427 received 360 000 € from Bpifrance to advance the pharmaceutical development of its first gene therapy candidate.

read more >

EG 427 recognised in iLab 2020
EG 427 recognised in iLab 2020

read more >

Events

EG 427 to present at Next Generation Gene Therapy Vectors 2024

EG 427 to present at Next Generation Gene Therapy Vectors 2024

2024-05-24
EG 427 at BIO International conference 2024

EG 427 at BIO International conference 2024

2024-05-14
EG 427 at BIO CEO and Investors 2024

EG 427 at BIO CEO and Investors 2024

2024-02-26
EG 427 at JP Morgan 2024

EG 427 at JP Morgan 2024

2023-12-18
EG 427 will be presenting at BioFuture

EG 427 will be presenting at BioFuture

2023-09-26
EG 427 to present at East/West Biopharm conference

EG 427 to present at East/West Biopharm conference

2023-09-18
EG 427 at International Continence Society 2023

EG 427 at International Continence Society 2023

2023-09-18
EG427 at BIO 2023

EG427 at BIO 2023

2023-09-18
Meet us at BIO €quity in Dublin

Meet us at BIO €quity in Dublin

2023-09-18
EG 427 will be presenting at BIO Europe Spring 2023

EG 427 will be presenting at BIO Europe Spring 2023

2023-02-07
See you at BioFIT 2022!

See you at BioFIT 2022!

2022-11-14

We'll be in BioFIT in Strasbourg on November 29-30, 2022. Our CEO, Philippe Chambon, will be presenting the company in the Startup Slam.

Come and meet us to learn more about nrHSV-1.

EG427 will be presenting at Bio-Europe Spring 2022

EG427 will be presenting at Bio-Europe Spring 2022

2022-11-04

Attend our presentation to know more about the company. Looking forward to e-meet you there!

Meet us at Cell Gene Med 2022 in Barcelona

Meet us at Cell Gene Med 2022 in Barcelona

2022-11-04

Our CEO, Philippe Chambon MD, PhD will be presenting EG 427 and our gene therapy platform.

×

Essential Cookies

These cookies are necessary for the website to function and cannot be turned off. They are used, for example, to maintain the contents of the user's basket. You can set your browser to block these cookies, but then the website will not function prope

Always active

Analytical cookies

These cookies allow you to count visits and traffic sources. Thanks to these files, it is known which pages are more popular and how the website visitors navigate. All information these cookies collect is anonymous.